These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18676755)

  • 1. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
    Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
    Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292).
    Wadler S; Bajaj R; Neuberg D; Agarwal V; Haynes H; Benson AB
    Cancer J Sci Am; 1997; 3(5):284-8. PubMed ID: 9327152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.
    Conzelmann M; Linnemann U; Berger MR
    Int J Oncol; 2004 Jun; 24(6):1537-44. PubMed ID: 15138598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver.
    Schimanski CC; Linnemann U; Berger MR
    Cancer Res; 1999 Oct; 59(20):5169-75. PubMed ID: 10537293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
    Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
    Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
    J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Aschele C; Debernardis D; Lonardi S; Bandelloni R; Casazza S; Monfardini S; Gallo L
    J Clin Oncol; 2004 Sep; 22(18):3758-65. PubMed ID: 15365072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
    Chazal M; Cheradame S; Formento JL; Francoual M; Formento P; Etienne MC; François E; Richelme H; Mousseau M; Letoublon C; Pezet D; Cure H; Seitz JF; Milano G
    Clin Cancer Res; 1997 Apr; 3(4):553-7. PubMed ID: 9815719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of K-ras mutations with liver metastases from colorectal carcinoma.
    Tsunoda A; Iijima T; Tsunoda Y; Nakao K; Miyaki M; Kusano M
    Anticancer Res; 2004; 24(4):2471-6. PubMed ID: 15330200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
    J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
    Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 mutations in colorectal cancer from northern Iran: Relationships with site of tumor origin, microsatellite instability and K-ras mutations.
    Mahdavinia M; Bishehsari F; Verginelli F; Cumashi A; Lattanzio R; Sotoudeh M; Ansari R; Semeraro D; Hormazdi M; Fakheri H; Rakhshani N; De Lellis L; Curia MC; Cama A; Piantelli M; Malekzadeh R; Iacobelli S; Mariani-Costantini R
    J Cell Physiol; 2008 Aug; 216(2):543-50. PubMed ID: 18330889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma.
    Berglund A; Edler D; Molin D; Nordlinder H; Graf W; Glimelius B
    Anticancer Res; 2002; 22(6B):3653-9. PubMed ID: 12552972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.